

## GABA<sub>B</sub> Receptor Subtypes Differentially Affect Synaptic Inhibition in the Dentate Gyrus

Joshua D Foster<sup>1</sup>, Ian Kitchen<sup>1</sup>, Bernhard Bettler<sup>2</sup>, Ying Chen<sup>1</sup>. <sup>1</sup>FHMS, University of Surrey, Guildford, UK, <sup>2</sup>Pharmazentrum, University of Basel, Basel, Switzerland.

GABA<sub>B</sub> receptors are G-protein-coupled receptors for the inhibitory neurotransmitter GABA. Two functional subtypes are expressed in the brain by combining a GABA<sub>B1</sub> isoform, GABA<sub>B1a</sub> or GABA<sub>B1b</sub>, with a GABA<sub>B2</sub> subunit. The GABA<sub>B(1a,2)</sub> receptors exclusively exert presynaptic inhibition on glutamate synapses, but both subtypes reduce GABA release. It is, however, unclear whether the subtypes are co-expressed or differentially localised on inhibitory pathways. We assessed the hypothesis that GABA<sub>B</sub> subtypes may differentially modulate synaptic inhibition by selective expression in inhibitory pathways.

We examined the function and localisation of GABA<sub>B</sub> receptors in the dentate gyrus of GABA<sub>B1</sub> isoform knockout mice using multielectrode electrophysiological recordings and immunohistochemical labelling. In the rat dentate gyrus, the predominant function of GABA<sub>B</sub> receptors is the enhancement of granule cell (GC) excitability via presynaptic inhibition of GABA release. Here, in murine dentate gyrus, GABA<sub>B</sub> receptor activation by the agonist, baclofen (10 μM), did not alter the excitatory synaptic transmission measured by the field excitatory postsynaptic potential ( $p > 0.05$ ), but increased the population spike of GCs in both the wild-type ( $142.7 \pm 6.1\%$  of control,  $n = 7$ ) and knockout mice ( $136.1 \pm 4.3\%$  ( $n = 9$ ) for GABA<sub>B1a</sub><sup>-/-</sup> mice and  $161.7 \pm 9.4\%$  ( $n = 6$ ) for GABA<sub>B1b</sub><sup>-/-</sup> mice). The significantly larger effect in GABA<sub>B1b</sub><sup>-/-</sup> mice ( $p < 0.001$ , repeated two-way ANOVA) indicated a more powerful effect by GABA<sub>B(1a,2)</sub> receptors. In addition, all baclofen-induced effects were prevented by the GABA<sub>B</sub> receptor antagonist CGP55845 (1 μM,  $p < 0.001$ , repeated two-way ANOVA), or GABA<sub>A</sub> receptor antagonist bicuculline (10 μM,  $n = 6$  mice from each genotype), showing a mechanism via GABA<sub>B</sub> receptor-mediated reduction of GABA release. Immunohistochemical labelling of GABA<sub>B1</sub> and GABA<sub>B2</sub> subunits highlighted cell body staining in hilar neurons and neuropil labelling in the molecular and GC layers. However, in GABA<sub>B1a</sub><sup>-/-</sup> mice neuropil staining in the inner molecular and GC layers was reduced together with the number of immunopositive hilar neurons at the hilus-GC border zone (by 24.3%,  $p < 0.05$ , one-way ANOVA with Tukey's multiple comparisons). In GABA<sub>B1b</sub><sup>-/-</sup> mice, in contrast, reduction of neuropil staining was found in the outer molecular layers, and the number of immunolabeled hilar neurons decreased at both the border zone (by 28.7%,  $p < 0.05$ ) and in deep layers (25.9%,  $p < 0.05$ ). GABA<sub>B(1a,2)</sub> receptors may, therefore, predominantly modulate GABA release from hilar projections onto the perisomatic and proximal dendritic regions of the GCs and thereby exert more powerful disinhibition than GABA<sub>B(1b,2)</sub> receptors, which control the distal dendritic fields. By selective expression in interneurons and their projections, GABA<sub>B</sub> receptor subtypes may, therefore, differentially modulate synaptic inhibition.

*The work was supported by the BBSRC.*